Published in Antimicrob Agents Chemother on February 17, 2009
Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors. Antimicrob Agents Chemother (2012) 1.00
Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase. Antimicrob Agents Chemother (2013) 0.82
The Need for Development of New HIV-1 Reverse Transcriptase and Integrase Inhibitors in the Aftermath of Antiviral Drug Resistance. Scientifica (Cairo) (2012) 0.76
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis (1995) 4.60
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol (1992) 3.46
In vitro selection and characterization of HIV-1 with reduced susceptibility to PMPA. Antivir Ther (1999) 2.85
Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis (2003) 2.30
Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother (1997) 2.15
A novel genetic pathway of human immunodeficiency virus type 1 resistance to stavudine mediated by the K65R mutation. J Virol (2003) 1.63
The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J Virol (2006) 1.59
Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS (1995) 1.58
K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther (2003) 1.42
Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob Agents Chemother (1997) 1.42
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative Group. J Infect Dis (2000) 1.37
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation. J Acquir Immune Defic Syndr (2008) 1.19
Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2'-deoxy-3'-oxa-4'-thiocytidine. Antimicrob Agents Chemother (1999) 1.11
In vitro activity of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor (NRTI), against 215 HIV-1 isolates resistant to other NRTIs. Antivir Chem Chemother (2005) 0.96
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC]. Antivir Chem Chemother (2000) 0.92
In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection. Antimicrob Agents Chemother (2006) 0.91
Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture. Antimicrob Agents Chemother (2004) 0.88
Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. AIDS (2006) 0.87
High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis (2007) 7.70
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS (2003) 3.60
HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS (2006) 2.77
Time to act: global apathy towards HIV/AIDS is a crime against humanity. Lancet (2002) 2.44
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens. Antimicrob Agents Chemother (2006) 2.23
Whither or wither microbicides? Science (2008) 2.17
Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus. AIDS (2003) 2.11
Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother (2003) 2.04
Methylation of Tat by PRMT6 regulates human immunodeficiency virus type 1 gene expression. J Virol (2005) 2.02
The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J Virol (2009) 2.00
Characterization of a putative alpha-helix across the capsid-SP1 boundary that is critical for the multimerization of human immunodeficiency virus type 1 gag. J Virol (2002) 1.96
Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol (2011) 1.95
Transmission networks of drug resistance acquired in primary/early stage HIV infection. AIDS (2008) 1.89
Development of antiretroviral drug resistance. N Engl J Med (2011) 1.88
Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol (2002) 1.84
Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT. Antimicrob Agents Chemother (2002) 1.82
Template usage is responsible for the preferential acquisition of the K65R reverse transcriptase mutation in subtype C variants of human immunodeficiency virus type 1. J Virol (2008) 1.79
Could chemoprophylaxis be used as an HIV prevention strategy while we wait for an effective vaccine? AIDS (2003) 1.78
Transmission clustering drives the onward spread of the HIV epidemic among men who have sex with men in Quebec. J Infect Dis (2011) 1.70
Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology (2013) 1.66
The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci U S A (2008) 1.64
Persistence of multidrug-resistant HIV-1 in primary infection leading to superinfection. AIDS (2004) 1.61
Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably? Retrovirology (2004) 1.59
Compensation by the E138K mutation in HIV-1 reverse transcriptase for deficits in viral replication capacity and enzyme processivity associated with the M184I/V mutations. J Virol (2011) 1.58
RIG-I-mediated antiviral signaling is inhibited in HIV-1 infection by a protease-mediated sequestration of RIG-I. J Virol (2010) 1.55
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir Ther (2003) 1.53
The role of surrogate markers in the clinical development of antiretroviral therapy: a model for early evaluation of targeted cancer drugs. Cancer Invest (2004) 1.50
Identification of novel mutations responsible for resistance to MK-2048, a second-generation HIV-1 integrase inhibitor. J Virol (2010) 1.46
Modification of the method of thread manufacture improves stroke induction rate and reduces mortality after thread-occlusion of the middle cerebral artery in young or aged rats. J Neurosci Methods (2006) 1.41
The XVI International Conference on AIDS: the place to be! Retrovirology (2006) 1.39
Coordinated RhoA signaling at the leading edge and uropod is required for T cell transendothelial migration. J Cell Biol (2010) 1.35
Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS (2012) 1.35
Tetherin restricts direct cell-to-cell infection of HIV-1. Retrovirology (2010) 1.34
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection. PLoS Med (2006) 1.34
Barriers to effective teaching. Acad Med (2011) 1.32
Arginine methylation of the human immunodeficiency virus type 1 Tat protein by PRMT6 negatively affects Tat Interactions with both cyclin T1 and the Tat transactivation region. J Virol (2007) 1.31
Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C. J Infect Dis (2009) 1.30
Chemoprophylaxis of HIV infection: moving forward with caution. J Infect Dis (2006) 1.28
Role of genetic diversity amongst HIV-1 non-B subtypes in drug resistance: a systematic review of virologic and biochemical evidence. AIDS Rev (2008) 1.27
Pre-exposure chemoprophylaxis (PREP) as an HIV prevention strategy. J Int Assoc Physicians AIDS Care (Chic) (2003) 1.27
Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob Agents Chemother (2006) 1.25
Role of RNA in facilitating Gag/Gag-Pol interaction. J Virol (2002) 1.25
Diminished efficiency of HIV-1 reverse transcriptase containing the K65R and M184V drug resistance mutations. AIDS (2007) 1.24
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
The role of unintegrated DNA in HIV infection. Retrovirology (2011) 1.23
Differential regulation of HIV-1 clade-specific B, C, and E long terminal repeats by NF-kappaB and the Tat transactivator. Virology (2002) 1.22
Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase. Antimicrob Agents Chemother (2013) 1.21
Mutation of the SP1 sequence impairs both multimerization and membrane-binding activities of human immunodeficiency virus type 1 Gag. J Virol (2005) 1.21
Cdc42 promotes transendothelial migration of cancer cells through β1 integrin. J Cell Biol (2012) 1.20
Diminished representation of HIV-1 variants containing select drug resistance-conferring mutations in primary HIV-1 infection. J Acquir Immune Defic Syndr (2004) 1.19
Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors. AIDS (2014) 1.19
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology (2013) 1.18
Antiretroviral therapy : optimal sequencing of therapy to avoid resistance. Drugs (2008) 1.17
Antiretroviral drug resistance in human immunodeficiency virus type 2. Antimicrob Agents Chemother (2009) 1.17
Stage-dependent inhibition of HIV-1 replication by antiretroviral drugs in cell culture. Antimicrob Agents Chemother (2009) 1.15
Evolution of HIV integrase resistance mutations. Curr Opin Infect Dis (2013) 1.13
Sequences downstream of the 5' splice donor site are required for both packaging and dimerization of human immunodeficiency virus type 1 RNA. J Virol (2003) 1.13
Emergence of embryonic pattern through contact inhibition of locomotion. Development (2012) 1.12
Mutations and polymorphisms associated with antiretroviral drugs in HIV-1C-infected African patients. Antivir Chem Chemother (2004) 1.12
HIV transmission and primary drug resistance. AIDS Rev (2006) 1.12
Drug resistance profiles of recombinant reverse transcriptases from human immunodeficiency virus type 1 subtypes A/E, B, and C. AIDS Res Hum Retroviruses (2003) 1.11
PRMT6 diminishes HIV-1 Rev binding to and export of viral RNA. Retrovirology (2006) 1.10
Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutation in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (2005) 1.10
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10
Variations in reverse transcriptase and RNase H domain mutations in human immunodeficiency virus type 1 clinical isolates are associated with divergent phenotypic resistance to zidovudine. Antimicrob Agents Chemother (2007) 1.10
The dual role of pharmacogenetics in HIV treatment: mutations and polymorphisms regulating antiretroviral drug resistance and disposition. Pharmacol Rev (2012) 1.10
Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes. Antimicrob Agents Chemother (2010) 1.08
Effects of the K65R and K65R/M184V reverse transcriptase mutations in subtype C HIV on enzyme function and drug resistance. Retrovirology (2009) 1.07
Novel therapeutic strategies targeting HIV integrase. BMC Med (2012) 1.06
The CRISPR/Cas9 system inactivates latent HIV-1 proviral DNA. Retrovirology (2015) 1.06
Multiple choices for HIV therapy with integrase strand transfer inhibitors. Retrovirology (2012) 1.06
Protease inhibitor resistance in HIV-infected patients: molecular and clinical perspectives. Antiviral Res (2007) 1.06